Table 4 Univariate analysis to assess the impact of dose factors on the appearance of CTCAE grad II-III toxicity and moist desquamation in 276 patients

52.9 (50.0–59.8)

52.9 (47.7–61.8)

0.91

52.9 (50.0–61.84)

53.1 (47.7–55.5)

0.34

53.3 (50.2–60.1)

53.4 (48.4–62.1)

0.64

52.4 (47.9–61.0)

52.6 (47.6–54.2)

0.93

36.5 (23.0–38.7)

36.6 (19.8–38.9)

0.66

36.6 (19.8–38.7)

36.4 (20.5–38.9)

0.10

0.4 (0.0–79.0)

0.8 (0–45.8)

0.54

0,6 (0–79.0)

1.3 (0–45.8)

0.04^*

0.3 (0.0–8.7)

0.6 (0.0–46.5)

0.27

0.4 (0.0–17.2)

0.9 (0.0–46.5)

0.03^*

124.7 (35.3–293.9)

134.3 (5.9–282.6)

0.06

126.9 (5.9–293.9)

147.7 (67.9–282.6)

< 0.01^*